Off-market insider buying at NervGen Pharma (V:NGEN)

Michael Kelly, a Senior Officer and Director, acquired 143,957 Common Shares on a direct ownership basis at a price of $2.350 through a prospectus or prospectus exempt offering on March 28th, 2024. The insider also acquired 71,978 Warrants with an exercise price of $3.000 for 36 months. This represents a $338,299 investment into the company's shares and an account share holdings change of greater than 100%.

Another Director also participated in smaller amount.

NervGen Pharma is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer's disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. The Company has two wholly owned subsidiaries, including NervGen US Inc. and NervGen Australia Pty Ltd.